Low‐dose rituximab every 6 months for the treatment of acetylcholine receptor–positive refractory generalized myasthenia gravis

In this prospective, open‐label study we explore the effectiveness of low‐dose rituximab every 6 months in treating refractory generalized myasthenia gravis (GMG).

[1]  C. Quan,et al.  Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis , 2019, Journal of Neuroimmunology.

[2]  P. Mccombe,et al.  Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[3]  Z. Siddiqi,et al.  Rituximab in refractory myasthenia gravis: Extended prospective study results , 2018, Muscle & nerve.

[4]  L. Wilkins.  2018 Emerging Science Abstracts , 2018, Neurology.

[5]  M. Guiguet,et al.  Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis. , 2018, Journal of neuromuscular diseases.

[6]  C. Quan,et al.  Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis , 2017, Journal of Neuroimmunology.

[7]  R. Kaji,et al.  Memory B cell resurgence requires repeated rituximab in myasthenia gravis , 2017, Neuromuscular Disorders.

[8]  R. Tandan,et al.  Rituximab treatment of myasthenia gravis: A systematic review , 2017, Muscle & nerve.

[9]  R. Martins,et al.  Rituximab in generalized myasthenia gravis: Clinical, quality of life and cost–utility analysis , 2017, Porto biomedical journal.

[10]  F. Bolgert,et al.  Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients , 2017, Neuromuscular Disorders.

[11]  J. Goldstein,et al.  Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody–Positive Myasthenia Gravis , 2017, JAMA neurology.

[12]  M. Benatar,et al.  International consensus guidance for management of myasthenia gravis , 2016, Neurology.

[13]  D. Drachman.  Treatment for Refractory Myasthenia Gravis-New Lymphs for Old. , 2016, JAMA neurology.

[14]  M. Ticchioni,et al.  Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis , 2016, Journal of Neuroimmunology.

[15]  M. Seishima,et al.  Efficacy of rituximab maintenance therapy for aggressive B-cell lymphoma depends on use of rituximab in induction therapy: a meta-analysis of randomized controlled trials , 2015, Haematologica.

[16]  Nils Erik Gilhus,et al.  Myasthenia gravis: subgroup classification and therapeutic strategies , 2015, The Lancet Neurology.

[17]  T. Cai,et al.  The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy , 2015, Journal of Neuroimmunology.

[18]  Kamal K Solanki,et al.  Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today? , 2015, Rheumatology.

[19]  V. Damato,et al.  Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis , 2015, Journal of Neurology.

[20]  M. Benatar,et al.  A randomized, double‐blind, placebo‐controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis , 2013, Muscle & nerve.

[21]  H. Tawbi,et al.  Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective , 2012, Critical Care.

[22]  M. Scully,et al.  Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura , 2010, Journal of thrombosis and haemostasis : JTH.

[23]  A. Vale,et al.  Clinical consequences of defects in B-cell development. , 2010, The Journal of allergy and clinical immunology.

[24]  R. Blesa,et al.  Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients , 2008, Journal of Neuroimmunology.

[25]  Robert H. Paul,et al.  Disease‐specific measure of quality of life for myasthenia gravis , 2008, Muscle & nerve.

[26]  D. Sanders,et al.  Mycophenolate mofetil for myasthenia gravis: An open-label pilot study , 2001, Neurology.

[27]  D B Sanders,et al.  Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. , 2000, Neurology.

[28]  R. Barohn,et al.  Myasthenia gravis , 2000, Neurology.

[29]  G. Wolfe,et al.  Myasthenia gravis activities of daily living profile , 1999, Neurology.